FDA advisers resoundingly rejected Acusphere's heart disease screening drug, saying that its risks significantly exceed any potential benefits. One of those risks includes abnormally low blood pressure, according to the AP. Acusphere had hoped that Imagify would become its first program to reach an FDA approval. Advisers voted 16 to 1 against that plan. Report